This summer, the Johns Hopkins spinout THRIVE raised an extra $257M for clinical trials of liquid biopsy cfDNA tests to detect occult cancers (here).
Today's emails brought me an invitation from QUEST to enroll in the THRIVE-ASCEND LBx trial, a large study to screen healthy people for possible occult cancers. Screen shot below.